01—Abstract
Summary
Summary of the 10-Q filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported third-quarter 2025 revenue of $1,004.9 milliona, down 0.5% from $1,009.8 million a year earlier, and nine-month revenue of $3,021.2 million, down 0.9%.
The filing attributes the declines mainly to lower volume in the DSA and Manufacturing segments, reflecting continued cautious client spending, partly offset by higher RMS revenue, which the filing ties primarily to Noveprim. Operating income rose to $133.8 millionb (13.3% of revenue) in the quarter from $117.4 million (11.6%), driven by lower severance costs and lower unallocated corporate compensation. For the nine months, operating income fell to $308.6 million (10.2% of revenue) from $395.0 million (13.0%), reflecting accelerated amortization of certain CDMO client relationships after the loss of key customers, higher restructuring and impairment charges, and higher third-party legal and advisory costs.
Below the operating line, earnings were pressured by $21.1 millionc of net losses and impairments on venture capital and strategic equity investments in the quarter. Net income available to common shareholders was $54.4 million for the quarter (diluted EPS of $1.10, versus $1.33) and $132.2 million for the nine months (diluted EPS of $2.65, versus $4.37). The effective tax rate rose to 36.3% in the quarter from 23.0%.
Nine-month operating cash flow was $590.1 milliond, up from $575.2 million. The company repurchased $350.0 million of stock during the nine months and, on October 29, 2025, approved a new $1.0 billion repurchase authorization. Management disclosed that DSA backlog declined to $1.8 billion from $2.0 billion, and that restructuring actions are expected to yield about $225 million of annualized cost savings.
In November 2025, the Board announced outcomes of its strategic review, including divesting certain underperforming or non-core assets (about 7% of estimated 2025 revenue) and initiatives expected to generate about $70 million of incremental annual net cost savings, fully realized in 2026. The company also remains subject to an SEC inquiry and securities and derivative litigation related to its non-human primate sourcing, which it says it believes lack merit and plans to defend vigorously.
02—Key points
Key Highlights
- Third-quarter revenue of $1,004.9 million decreased 0.5% year over year; nine-month revenue of $3,021.2 million decreased 0.9%.
- Third-quarter operating income rose to $133.8 million (13.3% of revenue) from $117.4 million (11.6%), while nine-month operating income fell to $308.6 million (10.2%) from $395.0 million (13.0%).
- Nine-month operating results include $71.0 million of accelerated amortization on certain CDMO client relationships tied to a loss of key customers, plus higher restructuring charges of $73.3 million.
- Diluted EPS was $1.10 for the quarter (vs. $1.33) and $2.65 for the nine months (vs. $4.37), reflecting $21.1 million of quarterly net losses and impairments on venture capital and strategic equity investments.
- DSA backlog declined to $1.8 billion from $2.0 billion, reflecting cautious client spending in the segment.
- The company repurchased $350.0 million of stock in the nine months, had $549.3 million remaining under the prior program, and approved a new $1.0 billion authorization on October 29, 2025.
- Strategic review outcomes announced in November 2025 include divesting non-core assets (about 7% of estimated 2025 revenue) and about $70 million of incremental annual net cost savings, fully realized in 2026.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed November 5, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $1.00B$1.01B | −0.5% |
| SG&A Expenses | $177.59M$199.21M | −10.9% |
| Operating Income | $133.80M$117.41M | +14.0% |
| Net Income | $54.42M$68.68M | −20.8% |
| EPS (Basic) | $1.11$1.34 | −17.2% |
| EPS (Diluted) | $1.10$1.33 | −17.3% |
| Shares Outstanding (Basic) | 49.21M51.39M | −4.2% |
| Shares Outstanding (Diluted) | 49.43M51.58M | −4.2% |
05—Questions
Frequently Asked Questions
Why did operating income improve in the third quarter but decline for the nine months?
The filing says third-quarter operating income increased primarily due to lower severance costs and lower unallocated corporate employee compensation. For the nine months, operating income decreased mainly due to accelerated amortization from the loss of key CDMO customers, higher restructuring activities including asset impairments and site consolidation charges, and higher third-party legal and advisory costs.
Why did net income available to common shareholders fall in the third quarter?
The filing attributes the quarterly decline principally to higher net losses and impairments on venture capital and strategic equity investments, partly offset by higher operating income. Other expense, net was $22.6 million in the quarter, compared with other income, net of $2.6 million a year earlier.
What is the company's liquidity and capital allocation position?
As of September 27, 2025, cash and cash equivalents were $207.1 million and total debt and finance leases were $2,201.4 million. The revolving facility had $665.5 million outstanding under a $2.0 billion credit facility maturing December 2029. The company repurchased $350.0 million of stock during the nine months and approved a new $1.0 billion repurchase authorization on October 29, 2025. The company states that existing funds, combined with operating cash flow and financing access, are sufficient to fund operations for the foreseeable future.
What are the main legal and regulatory matters investors should monitor?
The filing describes an ongoing SEC Enforcement Division inquiry related to non-human primate sourcing and disclosures, with the timing and outcome unpredictable. A securities class action was partially revived by the First Circuit on August 15, 2025, and two derivative lawsuits are stayed pending developments in that case. The company believes the class action and derivative suits lack merit and plans to defend them vigorously, and it cannot reasonably estimate potential exposure. The filing states that the DOJ's grand jury and parallel civil investigations were closed during the third fiscal quarter of 2025.
06—Continue